Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enerceptan vs Enbrel in Rheumatoid Arthritis
NCT03332719Phase 3Completed
- Sponsor
- Gema Biotech S.A.
- Start
- Feb 2016
- Primary completion
- Mar 2017
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of etanercept in rheumatoid arthritis (RA) (2 arms), sponsored by Gema Biotech S.A. Primary endpoint: American College of Rheumatology 20% Improvement at 32 weeks. Started Feb 2016; status: completed.
02
Drugs
etanercept
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT03332719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03332719.